Limited data about use of biosimilars (BIOs) are available in children with JIA. This study therefore aimed to evaluate long-term efficacy and safety of switching from etanercept (ETA) and adalimumab (ADA) originators to their biosimilars (BIOs), in children with JIA, in a real-world setting.
OBSIDIAN - real-world evidence of originator to biosimilar drug switch in juvenile idiopathic arthritis
Cattalini, Marco;
2022-01-01
Abstract
Limited data about use of biosimilars (BIOs) are available in children with JIA. This study therefore aimed to evaluate long-term efficacy and safety of switching from etanercept (ETA) and adalimumab (ADA) originators to their biosimilars (BIOs), in children with JIA, in a real-world setting.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
OBSIDIAN.pdf
accesso aperto
Descrizione: 10.1093/rheumatology/keab572
Tipologia:
Full Text
Licenza:
PUBBLICO - Creative Commons 4.0
Dimensione
301.64 kB
Formato
Adobe PDF
|
301.64 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
